Načítá se...
Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
New post hoc analysis of IPF clinical trials suggests that treatment with pirfenidone slows the worsening of patient-reported breathlessness over 12 months versus placebo in patients with more advanced disease (GAP stage II/III or FVC <80%) http://bit.ly/2yJyUVT
Uloženo v:
| Vydáno v: | Eur Respir J |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
European Respiratory Society
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6766683/ https://ncbi.nlm.nih.gov/pubmed/31164431 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.00399-2019 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|